Evidence map›Paper›PMID 36716407›Full record

Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2023

Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study.

Ursula A Matulonis, Domenica Lorusso, Ana Oaknin, Sandro Pignata, Andrew Dean, Hannelore Denys, Nicoletta Colombo, Toon Van Gorp, Jason A Konner, Margarita Romeo Marin and 7 more

Open access · hybridAbstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 230 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
230citing papers in PubMed, 6 pooled it
90.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

230 citing papers in PubMed, 6 syntheses or guidelines pooled it, 334 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Article
  17. Article
  18. Article
  19. Review
  20. Revisiting tumor immunogenicity through the lens of mutant p53: Implications for cancer immunotherapy.Apoptosis : an international journal on programmed cell death · 2026
    Review

170 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 14 institutions in 7 countries.

Ursula A MatulonisDana-Farber Cancer Institute, Boston, MA.ORCID 0000-0002-3103-6992
Domenica LorussoFondazione Policlinico Universitario A. Gemelli, IRCCS and Catholic University of Sacred Heart, Rome, Italy.ORCID 0000-0003-0981-0598
Ana OakninGynaecologic Cancer Programme, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.ORCID 0000-0002-3592-7194
Sandro PignataIstituto Nazionale Tumori di Napoli Fondazione G Pascale IRCCS, Naples, Italy.ORCID 0000-0002-8836-2633
Andrew DeanWA Medical Oncology St John of God Subiaco Hospital, Subiaco, WA, Australia.ORCID 0000-0001-6632-2799
Hannelore DenysGhent University Hospital, Ghent, Belgium.ORCID 0000-0002-8897-9430
Nicoletta ColomboEuropean Institute of Oncology IRCCS, Milan, Italy.ORCID 0000-0003-2225-715X
Toon Van GorpUniversity Hospital of Leuven, Leuven Cancer Institute, Leuven, Belgium.ORCID 0000-0002-2564-721X
Jason A KonnerMemorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0002-0720-2719
Margarita Romeo MarinInstitut Català d'Oncologia/Hospital Universitari Germans Trias i Pujol, Badalona, Spain.ORCID 0000-0003-1725-8115
Philipp HarterEv. Kliniken Essen-Mitte, Essen, Germany.ORCID 0000-0002-9663-5005
Conleth G MurphyBon Secours Hospital and Clinical Trials, Cork, Ireland.
Jiuzhou WangImmunoGen Inc, Waltham, MA.
Elizabeth NobleImmunoGen Inc, Waltham, MA.
Brooke EstevesImmunoGen Inc, Waltham, MA.
Michael MethodImmunoGen Inc, Waltham, MA.
Robert L ColemanUS Oncology Research, Texas Oncology, The Woodlands, TX.ORCID 0000-0001-9343-8754
ImmunoGen (United States) · USAgostino Gemelli University Polyclinic · ITBon Secours Hospital Cork · IEDana-Farber Cancer Institute · USEuropean Institute of Oncology · ITGhent University Hospital · BEInstitut Català d'Oncologia · ESIstituto Nazionale Tumori IRCCS "Fondazione G. Pascale" · ITKliniken Essen-Mitte · DEKU Leuven · BEMemorial Sloan Kettering Cancer Center · USSt John of God Subiaco Hospital · AUTexas Oncology · USVall d'Hebron Hospital Universitari · ES

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

purposeSingle-agent chemotherapies have limited activity and considerable toxicity in patients with platinum-resistant epithelial ovarian cancer (PROC). Mirvetuximab soravtansine (MIRV) is an antibody-drug conjugate targeting folate receptor α (FRα). SORAYA is a single-arm, phase II study evaluating efficacy and safety of MIRV in patients with PROC.

methodsSORAYA enrolled FRα-high patients with PROC who had received one to three prior therapies, including required bevacizumab. The primary end point was confirmed objective response rate (ORR) by investigator; duration of response was the key secondary end point.

resultsOne hundred six patients were enrolled; 105 were evaluable for efficacy. All patients had received prior bevacizumab, 51% had three prior lines of therapy, and 48% received a prior poly ADP-ribose polymerase inhibitor. Median follow-up was 13.4 months. ORR was 32.4% (95% CI, 23.6 to 42.2), including five complete and 29 partial responses. The median duration of response was 6.9 months (95% CI, 5.6 to 9.7). In patients with one to two priors, the ORR by investigator was 35.3% (95% CI, 22.4 to 49.9) and in patients with three priors was 30.2% (95% CI, 18.3 to 44.3). The ORR by investigator was 38.0% (95% CI, 24.7 to 52.8) in patients with prior poly ADP-ribose polymerase inhibitor exposure and 27.5% (95% CI, 15.9 to 41.7) in those without. The most common treatment-related adverse events (all grade and grade 3-4) were blurred vision (41% and 6%), keratopathy (29% and 9%), and nausea (29% and 0%). Treatment-related adverse events led to dose delays, reductions, and discontinuations in 33%, 20%, and 9% of patients, respectively.

conclusionMIRV demonstrated consistent clinically meaningful antitumor activity and favorable tolerability and safety in patients with FRα-high PROC who had received up to three prior therapies, including bevacizumab, representing an important advance for this biomarker-selected population.

Indexed as

Antineoplastic AgentsImmunoconjugatesOvarian NeoplasmsAdenosine Diphosphate RiboseAntibodies, Monoclonal, HumanizedBevacizumabCarcinoma, Ovarian EpithelialFemaleFolate Receptor 1HumansMaytansinePoly(ADP-ribose) Polymerase InhibitorsAdenosine Diphosphate RiboseAntibodies, Monoclonal, HumanizedAntineoplastic AgentsBevacizumabFolate Receptor 1ImmunoconjugatesMaytansinemirvetuximab soravtansinePoly(ADP-ribose) Polymerase Inhibitors

Identifiers

PMID36716407
PMCPMC10150846
OpenAlexW4318580181

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.